Greenville, South Carolina-based Premier Medical Laboratory Services (PMLS) is a highly sophisticated and top of the line advanced diagnostics lab. It offers robust diagnostic services comprising Covid-19 Antibody Testing, Pharmacogenomics, Advanced Cardiovascular Testing, Allergen-Specific Ige Blood testing, Women’s Health, and Wellness Panel, and also a revolutionary genetic test for diabetes—all under a single roof. “Usually, a patient is sent to different kinds of labs to get different types of testing done. This can cause inconvenience to the patients, delaying the time to get reports, and cause errors in compiling various reports. The tests that are performed by five to six labs, PMLS does them in a single lab, thereby eliminating all the challenges associated with multiple-lab testing,” remarks Tom Lee, COO at PMLS. The company has the latest equipment, such as liquid chromatography mass spectrometry (LCMS), Molecular, Allergy testing equipment, and the industry’s highest analytical standard. This not only allows the company to provide the most accurate interpretations but also the most rapid turnaround times for clinics and physicians. The company is fully certified by the Clinical Laboratory Improvement Amendments (CLIA) and the Commission on Office Laboratory Accreditation (COLA), and other major laboratory accrediting organizations.
“When you look at PMLS, our core value is we are here to address any of the physician or patients’ diagnostic needs,” states Lee. Leading the race in advanced genetic diagnostics, PMLS is the only lab in the country to offer a first-of-its-kind MDDiabeticPro panel, which includes a predictive genetic test for type 2 diabetes. Developed in collaboration with world-leading doctors and scientists of Harvard and MIT, the DIABETESpredict test is an effort to lessen the impact of global malice that diabetes is today.
Expected to mark a new era in diabetes prevention and care, the revolutionary MDDiabeticPro panel by PMLS uses DIABETESpredict to evaluate the risk of the disease onset by examining individual genetic profiles. Test results show whether a patient is at a high, medium, or low risk of developing type 2 diabetes. With a simple buccal swab or a blood sample, the DNA sequence of 16 single nucleotide polymorphisms (SNPs) is determined through a high performance genotyping platform at PMLS. Thereafter, the DIABETESpredict report provides individualized diet, exercise, and lifestyle recommendations informed by the genetic profile detected in each person. This information may support doctors in monitoring routines and lifestyle interventions to prevent type 2 diabetes and create customized plans for newly diagnosed diabetics that could save their lives. Once the customized recommendations are created for each patient, DIABETESpredict offers integrated wearable pedometers, smartphones, and web-based apps and games to aid patients in their treatment plan and help ensure that they stay on track.
Our goal is to do the testing in a manner that helps the physician catch things before they fully develop, which will help us deliver quality of life and potentially save lives along the way
Apart from their MDDiabeticPro panel breakthrough, PMLS provides an array of diagnostic panels comprising a full respiratory pathogen panel, GI panel, and Pharmacogenomics, which deals with how a patient metabolizes medications. At the same time, PMLS’ core laboratory runs a robust program intending to look into Advanced Cardiovascular markers. As more than 50 percent of patients with a heart attack or a stroke have a typical standard lipid panel, a lot is missed by just running that lipid panel. Hence, the cardiovascular panel by PMLS looks at advanced markers, such as inflammation markers, that get a much better picture of the patient’s cardiovascular health.
Using one of the most advanced laboratory information systems (LIS), OnGen LIS, PMLS generates easy to read one-page test result reports with higher accuracy and a customizable description for each client. PMLS can interface its LIS system to most EMR systems, thus providing clinics with faster access to a patient’s result reports and helps them run their clinic more efficiently while lowering operating costs.
On the backdrop of the pandemic, PMLS has been proactive in combating the spread of the virus by regularly ramping up their testing capacity while also acing the challenges on the way. One of the biggest problems out there right now is getting supplies. Labs in general that are focused on just laboratory services don’t have efficient supply chains that they can utilize or tap into. On the contrary, PMLS has its own supply chain formed out of the coordination with its sister companies who develop their own transport media and collection kits. That, in turn, has helped them in handling large volumes of samples daily. “Currently we have the capability to test 50,000 samples a day. We are now in the process of validating added machinery, as soon as they arrive, we would be able to hit the mark of testing 100,000 samples a day,” avidly affirms Michael Conroy, project manager and VP of Compliance at PMLS. He also elucidates that, “We are doing extensive research on our next gen sequence scene around the Covid-19 virus. We are mapping the genome and storing that data to get it out in the right hands, while also using our scientists and R&D team to look at different methods of sample collection and find as many ways possible to collect the sample.”
Alongside, PMLS is continually developing its HeartPro panel, which aims to replace the 40-year-old lipid panel with advanced lipid testing. By focusing on the Genetic Pro panel and cancer testing, they deliver quality test information that can help physicians change the treatment plan to prevent the patients from developing the disease. “Our goal is to do the testing in a manner that helps the physician catch things before they fully develop, which will help us deliver quality of life and potentially save lives along the way,” concludes Tom on a hopeful note.